Peptide 101: Tirzepatide (Mounjaro / Zepbound)

This is Peptide 101, where we take a single peptide and explain it plainly — what it is, how it works, what the evidence shows, and what to ask a clinician. The last two issues sat at opposite ends of the evidence spectrum: semaglutide, which you can fill at any pharmacy, and BPC-157, which has a devoted following and almost no completed human research. Tirzepatide sits firmly at the semaglutide end — FDA-approved, heavily trialed, and arguably the most powerful metabolic medication yet brought to market.

Peptide 101: Tirzepatide (Mounjaro / Zepbound)

Tirzepatide (Mounjaro/Zepbound) is an FDA-approved weekly injection that activates two metabolic hormones at once, making it more powerful than earlier GLP-1 medications. In clinical trials, it produced average weight loss of around 20%, approaching what surgical weight loss programs achieve. It is approved for both type 2 diabetes and obesity and has an expanding list of FDA-approved indications. Like all powerful medications, it requires medical supervision and lifelong continuation to maintain benefits.

How it works

Tirzepatide works on two ‘satiety switches’ in your body at the same time. GLP-1 turns down your appetite; GIP helps your body handle fat more efficiently. Together, they create a more powerful signal to eat less and burn stored energy more effectively than flipping either switch alone.

Tirzepatide is a single synthetic peptide that acts as a co-agonist at GIP and GLP-1 receptors. GLP-1 receptor activation reduces appetite, slows gastric emptying, increases satiety, and improves insulin secretion. GIP receptor activation further amplifies insulin and glucagon regulation, promotes fat storage reduction in adipose tissue via adiponectin, and may enhance brown adipose tissue thermogenesis. The synergistic dual-incretin mechanism produces greater glycemic control and weight reduction than either mechanism alone.

What the evidence shows

By our read, this one lands at Strong Evidence. A few of the studies behind that grade:

• SURMOUNT-1: Tirzepatide for obesity without diabetes — phase III RCT (2022) — At 72 weeks, tirzepatide 15 mg produced mean weight loss of 22.5% from baseline versus 2.4% placebo. 91% of participants achieved ≥5% weight loss at the highest dose.
• SURPASS-2: Tirzepatide versus semaglutide 1 mg in type 2 diabetes (2021) — Tirzepatide (5, 10, and 15 mg) achieved superior HbA1c reduction and significantly greater weight loss compared to semaglutide 1 mg at 40 weeks.
• SURMOUNT-OSA: Tirzepatide for obstructive sleep apnea (2024) — Tirzepatide significantly reduced apnea-hypopnea index and improved sleep-related quality of life in adults with obesity and moderate-to-severe OSA, supporting FDA approval for this indication.

Preliminary or early findings are not the same as proof. Any use beyond a peptide’s FDA-approved labeling (where one exists) is described here for educational purposes only and is not a recommendation.

Safety — the real risks

Nausea (most common, especially during dose escalation), vomiting, diarrhea, constipation, decreased appetite. Injection site reactions. Rare but serious: pancreatitis, cholelithiasis, diabetic retinopathy (in diabetics), hypoglycemia (when combined with insulin/sulfonylureas). Black box warning for thyroid C-cell tumors (based on rodent data — human relevance uncertain). Contraindicated in personal/family history of medullary thyroid carcinoma or MEN2.

Reasons to avoid it, or to talk to a clinician first:

• Personal or family history of medullary thyroid carcinoma (FDA boxed warning)
• Multiple endocrine neoplasia syndrome type 2 (MEN2) (FDA boxed warning)
• Known hypersensitivity to tirzepatide or any component
• History of pancreatitis
• Pregnancy or breastfeeding

This is not a complete safety list, and none of it is dosing advice.

Questions worth bringing to a clinician

• Am I a candidate for tirzepatide for diabetes management, weight management, or both?
• What is the expected trajectory of weight loss and how long should treatment continue?
• What are the risks of pancreatitis, thyroid C-cell tumors, and gallbladder disease with this medication?

New research, translated

CARTIZ: a registry watching what tirzepatide does to joints, heart, and body composition

2026-05 · observational registry · tirzepatide

A new observational registry in Mexico (CARTIZ) is following adults already taking tirzepatide and measuring, over time, what happens to their knee cartilage (via MRI), the fat around the heart (via cardiac CT), and their body composition. “Observational” is the key word: the study doesn’t start, stop, or change anyone’s treatment — it only records what unfolds. That design can surface associations worth investigating, but it cannot prove cause and effect. One to watch as the effects of these drugs get mapped beyond weight and blood sugar.

Source ↗

What readers are asking

Topics we’ll be tracking:

• Sustained Low-Dose Semaglutide Is Linked to Broad-Spectrum Cardiometabolic Benefits, and Better Tolerability Profile over Low-Dose Tirzepatide, Motivating Semaglutide Microdosing Studies
• Semaglutide and Tirzepatide in Type 1 Diabetes: Real-World Insulin Deintensification, Cardiovascular Outcomes and Safety Assessment
• Cardiovascular Outcomes with Tirzepatide versus Semaglutide in Type 2 Diabetes

Tirzepatide, in sum: a dual-hormone, FDA-approved drug with an unusually deep trial record and an expanding list of approved uses — alongside real risks that belong in a conversation with your own clinician. We will keep translating the research as the picture fills in.

— The Editors